Cosimo Commisso, Professor and Deputy Director, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, shared on LinkedIn:
“A randomized trial of a lymph node-targeted vaccine that trains the immune system to recognize mutant KRAS found that, overall, it did not significantly delay pancreatic cancer recurrence after surgery and chemotherapy.
But nearly all vaccinated patients (99%) mounted a strong immune response against the mutation, and those with the strongest responses stayed cancer-free much longer, according to a study with senior author Eileen O’Reilly at Memorial Sloan Kettering Cancer Center that is helping shape a larger follow-up trial.
Link.”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Authors: Ben George, Harshabad Singh, Craig E. Devoe, Vincent Chung, Peter J. Hosein, Andrew Hendifar, Dae Won Kim, Jennifer B. Valerin, Tanios Bekaii-Saab, Dana B. Cardin, Manuel Hidalgo, Pashtoon M. Kasi, Alexis D. Leal, Meredith Pelster, Naomi Fei, Colin D. Weekes, Mark H. O’Hara, Thomas J. George, Syed M. Kazmi, Jonathan D. Mizrahi, Suresh Nair, Martin Maiers, Thian Kheoh, Gianni Amato, Jino Xavier, Julia P. Snyder, Madison H. Milaszewski, Xavier Cabana-Puig, James R. Perry, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Zev A. Wainberg, Eileen M. O’Reilly.
Other articles featuring Cosimo Commisso on OncoDaily.